Skip to main content

Articles

Page 1 of 48

  1. Plasma mannose, an emerging novel biomarker of insulin resistance, is associated with both diabetes mellitus and coronary atherosclerosis, but the relationship between mannose concentrations and myocardial inf...

    Authors: Elena Fortin, Giulia Ferrannini, Beatrice Campi, Linda Mellbin, Anna Norhammar, Per Näsman, Alessandro Saba, Ele Ferrannini and Lars Rydén
    Citation: Cardiovascular Diabetology 2022 21:195
  2. Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney and heart failure events independent of glycemic effects. We assessed whether initiation of the SGLT2 inhibitor canagliflozin guided...

    Authors: Sok Cin Tye, Niels Jongs, Steven G. Coca, Johan Sundström, Clare Arnott, Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey, Priya Vart and Hiddo. J. L. Heerspink
    Citation: Cardiovascular Diabetology 2022 21:194
  3. The triglyceride glucose (TyG) index has been suggested as a reliable surrogate marker of insulin resistance which is a substantial risk factor for atherosclerotic cardiovascular disease (ASCVD). Several recen...

    Authors: Shinjeong Song, Su‑Yeon Choi, Hyo Eun Park, Hae‑Won Han, Sung Hak Park, Jidong Sung, Hae Ok Jung, Ji Min Sung and Hyuk‑Jae Chang
    Citation: Cardiovascular Diabetology 2022 21:193
  4. Glucokinase activators (GKAs) are an emerging class of glucose lowering drugs that activate the glucose-sensing enzyme glucokinase (GK). Pending formal cardiovascular outcome trials, we applied two-sample Mend...

    Authors: Ke Wang, Mai Shi, Chuiguo Huang, Baoqi Fan, Andrea O. Y. Luk, Alice P. S. Kong, Ronald C. W. Ma, Juliana C. N. Chan and Elaine Chow
    Citation: Cardiovascular Diabetology 2022 21:192
  5. Duodenal Mucosal Resurfacing (DMR) is an endoscopic ablation technique aimed at improving glycaemia and metabolic health in patients with type 2 diabetes mellitus (T2DM). DMR has an insulin sensitizing effect ...

    Authors: S. Meiring, C. B. E. Busch, A. C. G. van Baar, R. Hemke, F. Holleman, M. Nieuwdorp and J. J. G. H. M. Bergman
    Citation: Cardiovascular Diabetology 2022 21:191
  6. Post-acute sequelae of COVID-19 (PASC), also now known as long COVID, has become a major global health and economic burden. Previously, we provided evidence that there is a significant insoluble fibrin amyloid...

    Authors: Arneaux Kruger, Mare Vlok, Simone Turner, Chantelle Venter, Gert Jacobus Laubscher, Douglas B. Kell and Etheresia Pretorius
    Citation: Cardiovascular Diabetology 2022 21:190
  7. Scientific evidence has accumulated on the beneficial effects of nut consumption on cardiovascular risk and cholesterol reduction, but few studies have examined the effects of nuts on advanced measures of lipo...

    Authors: Jesús F. García-Gavilán, Margery A. Connelly, Nancy Babio, Christos S. Matzoros, Emilio Ros and Jordi Salas-Salvadó
    Citation: Cardiovascular Diabetology 2022 21:189
  8. Multivessel coronary disease (MVCD) is the common type of coronary artery disease in acute coronary syndrome (ACS). Coronary artery calcification (CAC) has been confirmed the strong predictor of major adverse ...

    Authors: Jiayu Wang, Xianwei Huang, Caihua Fu, Qiping Sheng and Ping Liu
    Citation: Cardiovascular Diabetology 2022 21:187
  9. The effect of dapagliflozin (DAPA) on the prognosis of patients with acute myocardial infarction (AMI) is unclear. The present study was conducted to evaluate the association between DAPA administration and ad...

    Authors: Yi Zhu, Jia-li Zhang, Xue-jiao Yan, Ling Sun, Yuan Ji and Fang-fang Wang
    Citation: Cardiovascular Diabetology 2022 21:186
  10. Future risk of cardiovascular disease (CVD) and mortality is associated with cumulative amount TyG index (cumTyG) exposure, while whether time course of TyG accumulation modulates the risk remains unclear. Thi...

    Authors: Xue Tian, Shuohua Chen, Yijun Zhang, Xiaoli Zhang, Qin Xu, Penglian Wang, Shouling Wu, Anxin Wang and Yanxia Luo
    Citation: Cardiovascular Diabetology 2022 21:183
  11. People with intermediate hyperglycemia (IH), including impaired fasting glucose and/or impaired glucose tolerance, are at higher risk of developing type 2 diabetes (T2D) than those with normoglycemia. We aimed...

    Authors: Shishi Xu, Ruth L. Coleman, Qin Wan, Yeqing Gu, Ge Meng, Kun Song, Zumin Shi, Qian Xie, Jaakko Tuomilehto, Rury R. Holman, Kaijun Niu and Nanwei Tong
    Citation: Cardiovascular Diabetology 2022 21:182
  12. The mechanism through which sodium-glucose cotransporter 2 inhibitors (SGLT2i) prevent the incidence of heart failure and/or affect cardiac structure and function remains unclear.

    Authors: Lorenzo Nesti, Nicola Riccardo Pugliese, Paolo Sciuto, Domenico Trico, Angela Dardano, Simona Baldi, Silvia Pinnola, Iacopo Fabiani, Vitantonio Di Bello and Andrea Natali
    Citation: Cardiovascular Diabetology 2022 21:181
  13. Patients with type 2 diabetes (T2DM) present an increased risk of cardiovascular (CV) disease and excess CV-related mortality. Beyond the established role of brain natriuretic peptide (BNP) and cardiac troponi...

    Authors: Jacopo Sabbatinelli, Angelica Giuliani, Anna Rita Bonfigli, Deborah Ramini, Giulia Matacchione, Carla Campolucci, Artan Ceka, Elena Tortato, Maria Rita Rippo, Antonio Domenico Procopio, Marco Moretti and Fabiola Olivieri
    Citation: Cardiovascular Diabetology 2022 21:180
  14. Gestational diabetes mellitus (GDM) is associated with adverse pregnancy outcomes and has maternal health implications reaching beyond the perinatal period. We aimed to investigate the incidence and severity o...

    Authors: Maria Hornstrup Christensen, Katrine Hass Rubin, Tanja Gram Petersen, Ellen Aagaard Nohr, Christina Anne Vinter, Marianne Skovsager Andersen and Dorte Moeller Jensen
    Citation: Cardiovascular Diabetology 2022 21:179
  15. Offspring of mothers with type 1 diabetes have an increased risk for acquiring early onset cardiovascular disease (CVD). Arterial stiffness, measured as pulse wave velocity (PWV), is a non-invasive biomarker f...

    Authors: Cedric A. Korpijaakko, Mia D. Eriksson, Niko S. Wasenius, Miira M. Klemetti, Kari Teramo, Hannu Kautiainen, Johan G. Eriksson and Merja K. Laine
    Citation: Cardiovascular Diabetology 2022 21:178
  16. Obesity is characterized by visceral fat accumulation and various metabolic disturbances that cause metabolic syndrome and obesity-related cardiovascular diseases (ORCVDs). Hence, treatments targeting obesity ...

    Authors: Kosuke Sawami, Atsushi Tanaka and Koichi Node
    Citation: Cardiovascular Diabetology 2022 21:176
  17. To compare the outcomes of diabetic patients hospitalized with non-ST elevation myocardial infarction (NSTEMI) or unstable angina (UA) referred for revascularization by either coronary artery bypass grafting (...

    Authors: Eilon Ram, Enrique Z. Fisman, Alexander Tenenbaum, Zaza Iakobishvili, Yael Peled, Ehud Raanani and Leonid Sternik
    Citation: Cardiovascular Diabetology 2022 21:175
  18. Extracellular vesicles are critical mediators of cell communication. They encapsulate a variety of molecular cargo such as proteins, lipids, and nucleic acids including miRNAs, lncRNAs, circular RNAs, and mRNA...

    Authors: Valeska Ormazabal, Soumyalekshmi Nair, Flavio Carrión, H. David Mcintyre and Carlos Salomon
    Citation: Cardiovascular Diabetology 2022 21:174
  19. Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates f...

    Authors: Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Shawn Gugliandolo, Camilla Cocchi, Umberto Capece, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano and Andrea Giaccari
    Citation: Cardiovascular Diabetology 2022 21:173
  20. Exploratory analysis to determine the effect of semaglutide versus comparators on high-sensitivity C-reactive protein (hsCRP) in subjects with type 2 diabetes.

    Authors: Ofri Mosenzon, Matthew S. Capehorn, Alessandra De Remigis, Søren Rasmussen, Petra Weimers and Julio Rosenstock
    Citation: Cardiovascular Diabetology 2022 21:172
  21. Osteoprotegerin (OPG) and osteopontin (OPN) are vascular calcification inhibitors with a known role in the atherosclerotic and inflammatory process. We investigated their relationship with adverse outcomes (re...

    Authors: Nikolaos P. E. Kadoglou, Dimitrios Kapetanios, Emmanouil Korakas, Georgia Valsami, Nikolaos Tentolouris, Nikolaos Papanas, Vaia Lambadiari and Christos Karkos
    Citation: Cardiovascular Diabetology 2022 21:171
  22. Gabapentin and pregabalin are commonly prescribed medications to treat pain in patients with diabetic neuropathy. Gabapentin and pregabalin can cause fluid retention, which is hypothesized to be associated wit...

    Authors: Yiheng Pan, Pamela B. Davis, David C. Kaebler, Robert P. Blankfield and Rong Xu
    Citation: Cardiovascular Diabetology 2022 21:170
  23. Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and ...

    Authors: Michael A. Nauck and David A. D‘Alessio
    Citation: Cardiovascular Diabetology 2022 21:169
  24. The triglyceride–glucose (TyG) index, which is a reliable surrogate marker of insulin resistance (IR), has been associated with cardiovascular diseases. However, evidence of the impact of the TyG index on the ...

    Authors: Xiang Wang, Wei Xu, Qirui Song, Zinan Zhao, Xuyang Meng, Chenxi Xia, Yibo Xie, Chenguang Yang, Pengfei Jin and Fang Wang
    Citation: Cardiovascular Diabetology 2022 21:168
  25. Plasma ceramides and sphingomyelins have been independently linked to diabetes risk, glucose and insulin levels, and the risk of several cardiovascular (CVD) outcomes. However, whether individual ceramide and ...

    Authors: Paul N. Jensen, Amanda M. Fretts, Andrew N. Hoofnagle, Barbara McKnight, Barbara V. Howard, Jason G. Umans, Colleen M. Sitlani, David S. Siscovick, Irena B. King, Nona Sotoodehnia and Rozenn N. Lemaitre
    Citation: Cardiovascular Diabetology 2022 21:167
  26. Among individuals with atherosclerotic cardiovascular disease (ASCVD), type 2 diabetes mellitus (T2DM) is common and confers increased risk for morbidity and mortality. Differentiating risk is key to optimize ...

    Authors: Susanna R. Stevens, Matthew W. Segar, Ambarish Pandey, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Eberhard Standl, Eric D. Peterson and Rury R. Holman
    Citation: Cardiovascular Diabetology 2022 21:166
  27. Cardiomyocyte death contributes to cardiac pathology of diabetes. Studies have shown that the RIPK3/MLKL necroptosis signaling is activated in diabetic hearts. Deletion of RIPK3 was reported to attenuate myoca...

    Authors: Ting Cao, Rui Ni, Weimin Ding, Xiaoyun Ji, Lan Li, Guangneng Liao, Yanrong Lu, Guo-Chang Fan, Zhuxu Zhang and Tianqing Peng
    Citation: Cardiovascular Diabetology 2022 21:165
  28. Continuous glucose monitoring (CGM) shows in more detail the glycaemic pattern of diabetic subjects and provides several new parameters (“glucometrics”) to assess patients’ glycaemia and consensually guide tre...

    Authors: Carlo Di Mario, Stefano Genovese, Gaetano A. Lanza, Edoardo Mannucci, Giancarlo Marenzi, Edoardo Sciatti and Dario Pitocco
    Citation: Cardiovascular Diabetology 2022 21:164
  29. Cardiovascular (CV) outcome trials (CVOTs) of type 2 diabetes mellitus (T2DM) therapies have mostly used randomized comparison with placebo to demonstrate non-inferiority to establish that the investigational ...

    Authors: Darren K. McGuire, David D’Alessio, Stephen J. Nicholls, Steven E. Nissen, Jeffrey S. Riesmeyer, Imre Pavo, Shanthi Sethuraman, Cory R. Heilmann, John J. Kaiser and Govinda J. Weerakkody
    Citation: Cardiovascular Diabetology 2022 21:163
  30. GLP-1 receptor agonists (GLP-1 RA) and SGLT-2 inhibitors (SGLT-2i) have shown to reduce the risk of major adverse cardiovascular events (MACE), death and worsening nephropathy when added to standard of care. H...

    Authors: Marta Baviera, Andreana Foresta, Pierluca Colacioppo, Giulia Macaluso, Maria Carla Roncaglioni, Mauro Tettamanti, Ida Fortino, Stefano Genovese, Irene Caruso and Francesco Giorgino
    Citation: Cardiovascular Diabetology 2022 21:162
  31. The triglyceride-glucose (TyG) index is a reliable surrogate marker of insulin resistance and is associated with major adverse cardiovascular events (MACEs) in patients with type 2 diabetes mellitus (T2DM). Ho...

    Authors: Shi Tai, Liyao Fu, Ningjie Zhang, Rukai Yang, Yuying Zhou, Zhenhua Xing, Yongjun Wang and Shenghua Zhou
    Citation: Cardiovascular Diabetology 2022 21:161
  32. It is well known that diabetes is a prominent risk factor for cardiovascular (CV) events. The level of CV risk depends on the type and duration of diabetes, age and additional co-morbidities. Diabetes is an in...

    Authors: A. John Camm, Hani Sabbour, Oliver Schnell, Francesco Summaria and Atul Verma
    Citation: Cardiovascular Diabetology 2022 21:160
  33. Treatment algorithms define lines of glucose lowering medications (GLM) for the management of type 2 diabetes (T2D), but whether therapeutic trajectories are associated with major adverse cardiovascular events...

    Authors: Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Angelo Avogaro and Gian Paolo Fadini
    Citation: Cardiovascular Diabetology 2022 21:159
  34. The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. A composite that captures information from both may provide a simpler w...

    Authors: Hertzel C. Gerstein, Chinthanie Ramasundarahettige, Alvero Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Gilles R. Dagenais, Edward Franek, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Nana Pogosova, Jeffrey Probstfield, Peter J. Raubenheimer, Matthew Riddle, Jonathan Shaw…
    Citation: Cardiovascular Diabetology 2022 21:158
  35. There is a lack of recent data reflecting the actual use of sodium-glucose cotransporter-2 (SGLT2) inhibitors for heart failure (HF) and type 2 diabetes (DM) in the superaged society. The present study investi...

    Authors: Michikazu Nakai, Yoshitaka Iwanaga, Koshiro Kanaoka, Yoko Sumita, Yuichi Nishioka, Tomoya Myojin, Shinichiro Kubo, Katsuki Okada, Tsunenari Soeda, Tatsuya Noda, Yasushi Sakata, Tomoaki Imamura, Yoshihiko Saito, Satoshi Yasuda and Yoshihiro Miyamoto
    Citation: Cardiovascular Diabetology 2022 21:157
  36. Inflammation plays a crucial role in the pathogenesis and progression of coronary artery disease (CAD). The neutrophil to lymphocyte ratio (NLR) is a novel inflammatory biomarker and its association with clini...

    Authors: Jining He, Xiaohui Bian, Chenxi Song, Rui Zhang, Sheng Yuan, Dong Yin and Kefei Dou
    Citation: Cardiovascular Diabetology 2022 21:156
  37. This study aimed to investigate the associations between the triglyceride-glucose (TyG) index in young adulthood with incident cardiovascular disease (CVD) and mortality.

    Authors: Xinghao Xu, Rihua Huang, Yifen Lin, Yue Guo, Zhenyu Xiong, Xiangbin Zhong, Xiaomin Ye, Miaohong Li, Xiaodong Zhuang and Xinxue Liao
    Citation: Cardiovascular Diabetology 2022 21:155
  38. Reduced cholesterol efflux capacity (CEC) of HDLs is likely to increase cardiovascular risk in type 1 diabetes (T1D). We aimed to assess whether improvement of glycemic control in T1D patients is associated wi...

    Authors: Damien Denimal, Serge Monier, Isabelle Simoneau, Laurence Duvillard, Bruno Vergès and Benjamin Bouillet
    Citation: Cardiovascular Diabetology 2022 21:154
  39. Prediabetes is an important risk factor of cardiovascular disease (CVD) and is associated with subclinical atherosclerosis. However, the evidence of prediabetes as a cardiovascular risk factor is mainly derive...

    Authors: Qiuyu Cao, Zhuojun Xin, Ruixin He, Tiange Wang, Min Xu, Jieli Lu, Meng Dai, Di Zhang, Yuhong Chen, Zhiyun Zhao, Shuangyuan Wang, Hong Lin, Weiqing Wang, Guang Ning, Yufang Bi, Yu Xu…
    Citation: Cardiovascular Diabetology 2022 21:153
  40. Impaired glucose tolerance (IGT) has been related to adverse cardiovascular outcomes. We investigated the added value of 1-h plasma glucose (PG) at the oral glucose tolerance test (OGTT) in predicting admissio...

    Authors: Viola Zywicki, Paola Capozza, Paolo Caravelli, Stefano Del Prato and Raffaele De Caterina
    Citation: Cardiovascular Diabetology 2022 21:152
  41. Insulin resistance and hyperinsulinemia in patients with type 2 diabetes (T2D) are adversely associated with the development and worsening of heart failure (HF). Herein, we sought to investigate the effect of ...

    Authors: Atsushi Tanaka, Takumi Imai, Michio Shimabukuro, Isao Taguchi, Akira Sezai, Shigeru Toyoda, Hirotaka Watada, Junya Ako and Koichi Node
    Citation: Cardiovascular Diabetology 2022 21:151
  42. Chronic total occlusion (CTO) of the coronary artery is a difficult problem in clinical practice. The triglycerideglucose (TyG) index is an effective risk predictor of cardiovascular risk. However, the relations...

    Authors: Yingkai Li, Songyuan He, Zheng Wu, Wenzheng Li, Wen Jian, Zichao Cheng, Cong Wang, Yuchen Shi and Jinghua Liu
    Citation: Cardiovascular Diabetology 2022 21:149
  43. Fibrin(ogen) amyloid microclots and platelet hyperactivation previously reported as a novel finding in South African patients with the coronavirus 2019 disease (COVID-19) and Long COVID/Post-Acute Sequelae of ...

    Authors: Etheresia Pretorius, Chantelle Venter, Gert Jacobus Laubscher, Maritha J Kotze, Sunday O. Oladejo, Liam R. Watson, Kanshu Rajaratnam, Bruce W. Watson and Douglas B. Kell
    Citation: Cardiovascular Diabetology 2022 21:148
  44. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve endothelial dysfunction and reduce cardiovascular events in individuals with type 2 diabetes (T2D). Proprotein convertase subtilisin/kexin 9 (PCSK9i) ...

    Authors: Andrei C. Sposito, Ikaro Breder, Joaquim Barreto, Jessica Breder, Isabella Bonilha, Marcus Lima, Alessandra Oliveira, Vaneza Wolf, Beatriz Luchiari, Helison R. do Carmo, Daniel Munhoz, Daniela Oliveira, Otavio R. Coelho-Filho, Otavio R. Coelho, Jose Roberto Matos-Souza, Filipe A. Moura…
    Citation: Cardiovascular Diabetology 2022 21:147
  45. The Global Registry of Acute Coronary Events (GRACE) score derived from clinical parameters at the time of hospital discharge is a powerful predictor of long-term mortality and reinfarction after acute coronar...

    Authors: Shiqiang Xiong, Qiang Chen, Xu Chen, Jun Hou, Yingzhong Chen, Yu Long, Siqi Yang, Lingyao Qi, Hong Su, Wenchao Huang, Hanxiong Liu, Zhen Zhang and Lin Cai
    Citation: Cardiovascular Diabetology 2022 21:145

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Annual Journal Metrics